- Investigator Sponsored Study
- First patient dosed in September 2020
- Approx 18 patients
- Recurrent/progressive glioblastoma
- Assess safety
- Determine the maximum tolerated dose schedule (MTD) and a recommended Phase 2 dosing plan (RP2D)
- Estimate: six month progression free survival (PFS) rate; nine month overall survival (OS) rate: median overall survival (OS)
- Principal Investigator – Prof Behnam Badie at COH
- Currently screening patients
ClinicTrials.gov – CAR-T Cells with a Chlorotoxin Tumor-Targeting Domain for Glioblastoma
*None of Chimeric’s product pipeline has received marketing authorization in any jurisdiction. Any use of Chimeric’s products is on an investigational basis or for use in approved clinical trials.
